Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes

February 25, 2014 at 08:01 AM EST

[PR Newswire] – INDIANAPOLIS, Feb. 25, 2014 /PRNewswire/ — Eli Lilly and Company (LLY) today announced positive top-line results of the sixth AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trial for . . . → Read More: Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes Similar Articles: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA panel backs Bristol diabetes drug after prior rejection The Boeing Company (NYSE:BA) – Boeing reports 17 new orders in weekly update Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Xigduo™ (dapagliflozin and metformin hydrochloride) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes

Eli Lilly & Company (NYSE:LLY) [PR Newswire] – INDIANAPOLIS, Feb. 25, 2014 /PRNewswire/ — Eli Lilly and Company (LLY) today announced positive top-line results of the sixth AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trial for once-weekly dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a treatment for type 2 diabetes. In the AWARD-6 study, once-weekly dulaglutide 1.5 mg achieved the primary endpoint of … [visit site to read more]